A study reported that combining OAds with anti-PD-1 therapy plus a CSF-1 receptor inhibitor greatly enhanced tumor regression and overall survival, which were achieved through increased functional T cell infiltration and anti-tumor phenotype conversion of TAMs [135]. This evidence concerns the gene PDCD1 and neoplasm.